ABBV vs MRK

For growth investors, AbbVie Inc.

(ABBV) is the stronger pick with 8. 6% revenue growth year-over-year, versus 1. 2% for Merck & Co. , Inc. (MRK). Merck & Co. , Inc. (MRK) offers the better valuation at 15. 6x trailing P/E (22. 2x forward), making it the more compelling value choice. Analysts rate AbbVie Inc. (ABBV) a "Buy" — based on 41 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Merck & Co.

, Inc. (MRK) is the cheapest at 15. 6x versus AbbVie Inc. at 86. 5x. On forward P/E, AbbVie Inc. is actually cheaper at 14. 4x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, AbbVie Inc.

(ABBV) delivered a total return of +102. 8%, compared to +73. 3% for Merck & Co. , Inc. (MRK). Over 10 years, the gap is even starker: ABBV returned +306. 7% versus MRK's +171. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AbbVie Inc.

(ABBV) is the lower-risk stock at 0. 34β versus Merck & Co. , Inc. 's 0. 48β — meaning MRK is approximately 41% more volatile than ABBV relative to the S&P 500.

By revenue growth (latest reported year), AbbVie Inc.

(ABBV) is pulling ahead at 8. 6% versus 1. 2% for Merck & Co. , Inc. (MRK). On earnings-per-share growth, the picture is similar: Merck & Co. , Inc. grew EPS 8. 0% year-over-year, compared to -0. 8% for AbbVie Inc.. Over a 3-year CAGR, MRK leads at 3. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Merck & Co.

, Inc. (MRK) is the more profitable company, earning 28. 1% net margin versus 6. 9% for AbbVie Inc. — meaning it keeps 28. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MRK leads at 36. 2% versus 32. 8% for ABBV. At the gross margin level — before operating expenses — MRK leads at 72. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, AbbVie Inc.

(ABBV) trades at 14. 4x forward P/E versus 22. 2x for Merck & Co. , Inc. — 7. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ABBV: 25. 2% to $256. 64.

All stocks in this comparison pay dividends.

AbbVie Inc. (ABBV) offers the highest yield at 3. 2%, versus 2. 9% for Merck & Co. , Inc. (MRK).

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 34), 3. 2% yield, +306. 7% 10Y return). Both have compounded well over 10 years (ABBV: +306. 7%, MRK: +171. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ABBV is a large-cap income-oriented stock; MRK is a large-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.